Literature DB >> 15225728

A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist.

Brian H Heasley1, Renata Jarosz, Karen M Carter, S Jenny Van, Kevin R Lynch, Timothy L Macdonald.   

Abstract

A recently reported dual LPA(1)/LPA(3) receptor antagonist (1) has been modified so as to modulate the basicity, sterics, and dipole moment of the 2-pyridyl moiety. Additionally, the implications of installing nonhydrolyzable phosphate head group isosteres with regard to antagonist potency and selectivity at LPA receptors is described. This study has resulted in the development of the first nonhydrolyzable and presumably phosphatase-resistant LPA(3)-selective antagonist reported to date.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225728     DOI: 10.1016/j.bmcl.2004.05.023

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

3.  Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.

Authors:  Peng Cui; Jose L Tomsig; William F McCalmont; Sangderk Lee; Christopher J Becker; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

4.  2D binary QSAR modeling of LPA3 receptor antagonism.

Authors:  James I Fells; Ryoko Tsukahara; Jianxiong Liu; Gabor Tigyi; Abby L Parrill
Journal:  J Mol Graph Model       Date:  2010-03-07       Impact factor: 2.518

5.  Identification of non-lipid LPA3 antagonists by virtual screening.

Authors:  James I Fells; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; Donna H Perygin; Daniel A Osborne; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

6.  Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.

Authors:  James E East; Karen M Carter; Perry C Kennedy; Nancy A Schulte; Myron L Toews; Kevin R Lynch; Timothy L Macdonald
Journal:  Medchemcomm       Date:  2011-03-03       Impact factor: 3.597

7.  LPA Stimulates the Phosphorylation of p130Cas via Gαi2 in Ovarian Cancer Cells.

Authors:  Jeremy D Ward; Danny N Dhanasekaran
Journal:  Genes Cancer       Date:  2012-09

8.  Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure.

Authors:  Manikandan Panchatcharam; Sumitra Miriyala; Fanmuyi Yang; Mauricio Rojas; Christopher End; Christopher Vallant; Anping Dong; Kevin Lynch; Jerold Chun; Andrew J Morris; Susan S Smyth
Journal:  Circ Res       Date:  2008-08-14       Impact factor: 17.367

Review 9.  Lysophospholipid interactions with protein targets.

Authors:  Abby L Parrill
Journal:  Biochim Biophys Acta       Date:  2008-05-02

10.  Structure-based drug design identifies novel LPA3 antagonists.

Authors:  James I Fells; Ryoko Tsukahara; Jianxiong Liu; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2009-09-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.